Market Cap (In SEK)
46.44 Million
Revenue (In SEK)
3000.00
Net Income (In SEK)
-15.9 Million
Avg. Volume
40.11 Thousand
- Currency
- SEK
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 2.62-12.1
- PE
- -
- EPS
- -
- Beta Value
- 1.158
- ISIN
- SE0015504097
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Stian Kildal
- Employee Count
- -
- Website
- https://www.oncozenge.se
- Ipo Date
- 2021-02-12
- Details
- OncoZenge AB (publ), a pharmaceutical company, develops healthcare products for cancer supportive care. It offers BupiZenge, which has completed Phase 2 clinical trial for the treatment of oral mucositis. The company was founded in 2020 and is headquartered in Bromma, Sweden. OncoZenge AB (publ) is a subsidiary of Moberg Pharma AB (publ).
More Stocks
-
ELECON
-
AZMTFAzimut Exploration Inc.
AZMTF
-
RSAURooshine, Inc.
RSAU
-
CANF
-
CPOF
-
EMLEmmerson PLC
EML
-
PRAXISPraxis Home Retail Limited
PRAXIS
-
MMNDMastermind, Inc.
MMND